[Seite 68↓]

Referenzliste

[1] Rosenbaum, M.; Leibel, R. L. und Hirsch, J. (1997): Obesity, N.Engl.J.Med. 337, Seite 396-407.

[2] Flegal, K. M.; Carroll, M. D.; Kuczmarski, R. J. und Johnson, C. L. (1998): Overweight and obesity in the United States: prevalence and trends, 1960-1994, Int.J.Obes.Relat Metab Disord. 22 [1], Seite 39-47.

[3] Popkin, B. M. und Doak, C. M. (1998): The obesity epidemic is a worldwide phenomenon, Nutr.Rev. 56 [4 Pt 1], Seite 106-114.

[4] Wadden, T. A. und Foster, G. D. (2000): Behavioral treatment of obesity, Med.Clin.North Am. 84 [2], Seite 441-61, vii.

[5] Yanovski, Susan Z. und Yanovski, Jack A. (2002): Obesity, N.Engl.J.Med. 346 [8], Seite 591-602.

[6] Heal, D. J.; Aspley, S.; Prow, M. R.; Jackson, H. C.; Martin, K. F. und Cheetham, S. C. (1998): Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine, Int.J.Obes.Relat Metab Disord. 22 Suppl 1S18-28; discussion S29-28.

[7] Luscombe, G. P.; Slater, N. A.; Lyons, M. B.; Wynne, R. D.; Scheinbaum, M. L. und Buckett, W. R. (1990): Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl, Psychopharmacology (Berl) 100, Seite 345-349.

[8] Cheetham, S. C.; Viggers, J. A.; Slater, N. A.; Heal, D. J. und Buckett, W. R. (1993): [3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments, Neuropharmacology 32, Seite 737-743.

[9] Cheetham, S. C.; Viggers, J. A.; Butler, S. A.; Prow, M. R. und Heal, D. J. (1996): [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments, Neuropharmacology 35, Seite 63-70.

[10] Connoley, I. P.; Liu, Y. L.; Frost, I.; Reckless, I. P.; Heal, D. J. und Stock, M. J. (1999): Thermogenic effects of sibutramine and its metabolites, Br.J.Pharmacol. 126 [6], Seite 1487-1495.

[11] Casado, A.; Rodriguez, V. M.; Portillo, M. P.; Macarulla, M. T.; Abecia, L. C.; Echevarria, E. und Casis, L. (2003): Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins, Nutr.Neurosci. 6 [2], Seite 103-111.

[12] Hansen, D. L.; Toubro, S.; Stock, M. J.; Macdonald, I. A. und Astrup, A. (1998): Thermogenic effects of sibutramine in humans, Am.J.Clin.Nutr. 68 [6], Seite 1180-1186.

[13] Walsh, K. M.; Leen, E. und Lean, M. E. (1999): The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females, Int.J.Obes.Relat Metab Disord. 23 [10], Seite 1009-1015.

[14] Starling, R. D.; Liu, X. und Sullivan, D. H. (2001): Influence of sibutramine on energy expenditure in African American women, Obes.Res. 9 [4], Seite 251-256.

[15] James, W. P.; Astrup, A.; Finer, N.; Hilsted, J.; Kopelman, P.; Rossner, S.; Saris, W. H. und Van Gaal, L. F. (2000): Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance, Lancet 356 [9248], Seite 2119-2125.

[16] Bray, G. A.; Ryan, D. H.; Gordon, D.; Heidingsfelder, S.; Cerise, F. und Wilson, K. (1996): A double-blind randomized placebo-controlled trial of sibutramine, Obes.Res. 4 [3], Seite 263-270.

[17] Cuellar, G. E.; Ruiz, A. M.; Monsalve, M. C. und Berber, A. (2000): Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population, Obes.Res. 8 [1], Seite 71-82.

[18] Lundberg, J. M. (1996): Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide, Pharmacol.Rev. 48, Seite 113-178.

[19] Esler, M.; Jennings, G.; Lambert, G.; Meredith, I.; Horne, M. und Eisenhofer, G. (1990): Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions, Physiol Rev. 70, Seite 963-985.

[20] Bachman, E. S.; Dhillon, H.; Zhang, C. Y.; Cinti, S.; Bianco, A. C.; Kobilka, B. K. und Lowell, B. B. (2002): betaAR signaling required for diet-induced thermogenesis and obesity resistance, Science 297 [5582], Seite 843-845.

[21] Ordway, G. A.; Stockmeier, C. A.; Cason, G. W. und Klimek, V. (1997): Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei, J.Neurosci. 17, Seite 1710-1719.

[22] Olivier, B.; Soudijn, W. und van, Wijngaarden, I (2000): Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors, Prog.Drug Res.2000.;54.:59.-119. 54, Seite 59-119.

[23] Risch, S. C. und Nemeroff, C. B. (1992): Neurochemical alterations of serotonergic neuronal systems in depression, J.Clin.Psychiatry 53 Suppl, Seite 3-7.

[24] Barnes, N. M. und Sharp, T. (1999): A review of central 5-HT receptors and their function, Neuropharmacology 38, Seite 1083-1152.

[25] Ramamoorthy, S.; Bauman, A. L.; Moore, K. R.; Han, H.; Yang-Feng, T.; Chang, A. S.; Ganapathy, V. und Blakely, R. D. (1993): Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization, Proc.Natl.Acad.Sci.U.S.A 90, Seite 2542-2546.

[26] Takata, T. S.; Wasmund, S. L.; Smith, M. L.; Li, J. M.; Joglar, J. A.; Banks, K.; Kowal, R. C.; Page, R. L. und Hamdan, M. H. (2002): Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers, Circulation 106 [12], Seite 1500-1504.

[27] Glassman, A. H.; O'Connor, C. M.; Califf, R. M.; Swedberg, K.; Schwartz, P.; Bigger, J. T., Jr.; Krishnan, K. R.; van Zyl, L. T.; Swenson, J. R.; Finkel, M. S.; Landau, C.; Shapiro, P. A.; Pepine, C. J.; Mardekian, J.; Harrison, W. M.; Barton, D. und Mclvor, M. (2002): Sertraline treatment of major depression in patients with acute MI or unstable angina, JAMA 288 [6], Seite 701-709.

[28] Andrews, C. und Pinner, G. (1998): Postural hypotension induced by paroxetine, BMJ 316 [7131], Seite 595.

[29] Schroeder, Christoph; Tank, Jens; Boschmann, Michael; Diedrich, Andre; Sharma, Arya M.; Biaggioni, Italo; Luft, Friedrich C. und Jordan, Jens (2002): Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance, Circulation 105 [3], Seite 347-353.

[30] Tank, J.; Schroeder, C.; Diedrich, A.; Szczech, E.; Haertter, S.; Sharma, A. M.; Luft, F. C. und Jordan, J. (2003): Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition, Circulation 107 [23], Seite 2949-2954.

[31] Pacholczyk, T.; Blakely, R. D. und Amara, S. G. (1991): Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter, Nature 350, Seite 350-354.

[32] Ross, R. J.; Zavadil, A. P., III; Calil, H. M.; Linnoila, M.; Kitanaka, I.; Blombery, P.; Kopin, I. J. und Potter, W. Z. (1983): Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure, Clin.Pharmacol.Ther. 33, Seite 429-437.

[33] Esler, M. D.; Wallin, G.; Dorward, P. K.; Eisenhofer, G.; Westerman, R.; Meredith, I.; Lambert, G.; Cox, H. S. und Jennings, G. (1991): Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans, Am.J.Physiol 260 [4 Pt 2], Seite R817-R823.

[34] Eisenhofer, G.; Saigusa, T.; Esler, M. D.; Cox, H. S.; Angus, J. A. und Dorward, P. K. (1991): Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits, Am.J.Physiol 260 [4 Pt 2], Seite R824-R832.

[35] Kim, S. H.; Lee, Y. M.; Jee, S. H. und Nam, C. M. (2003): Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials, Obes.Res. 11 [9], Seite 1116-1123.

[36] Hirsch, J.; Mackintosh, R. M. und Aronne, L. J. (2000): The effects of drugs used to treat obesity on the autonomic nervous system, Obes.Res. 8 [3], Seite 227-233.

[37] Grassi, G.; Seravalle, G.; Cattaneo, B. M.; Bolla, G. B.; Lanfranchi, A.; Colombo, M.; Giannattasio, C.; Brunani, A.; Cavagnini, F. und Mancia, G. (1995): Sympathetic activation in obese normotensive subjects, Hypertension 25, Seite 560-563.

[38] Mark, A. L.; Correia, M.; Morgan, D. A.; Shaffer, R. A. und Haynes, W. G. (1999): State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity, Hypertension 33 [1 Pt 2], Seite 537-541.

[39] Rumantir, M. S.; Vaz, M.; Jennings, G. L.; Collier, G.; Kaye, D. M.; Seals, D. R.; Wiesner, G. H.; Brunner-La Rocca, H. P. und Esler, M. D. (1999): Neural mechanisms in human obesity-related hypertension, J.Hypertens. 17 [8], Seite 1125-1133.

[40] Engeli, S. und Sharma, A. M. (2001): The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension, J.Mol.Med. 79 [1], Seite 21-29.

[41] Gundlah, C.; Martin, K. F.; Heal, D. J. und Auerbach, S. B. (1997): In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor, J.Pharmacol.Exp.Ther. 283 [2], Seite 581-591.

[42] Buckett, W. R.; Thomas, P. C. und Luscombe, G. P. (1988): The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation, Prog.Neuropsychopharmacol.Biol.Psychiatry 12 [5], Seite 575-584.

[43] Cheetham, S. C.; Kettle, C. J.; Martin, K. F. und Heal, D. J. (1995): D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function, J.Neural Transm.Gen.Sect. 102, Seite 35-46.

[44] Glick, S. D.; Haskew, R. E.; Maisonneuve, I. M.; Carlson, J. N. und Jerussi, T. P. (2000): Enantioselective behavioral effects of sibutramine metabolites, Eur.J.Pharmacol. 397 [1], Seite 93-102.

[45] Luque, C. A. und Rey, J. A. (1999): Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity, Ann.Pharmacother. 33 [9], Seite 968-978.

[46] Hind, I. D.; Mangham, J. E.; Ghani, S. P.; Haddock, R. E.; Garratt, C. J. und Jones, R. W. (1999): Sibutramine pharmacokinetics in young and elderly healthy subjects, Eur.J.Clin.Pharmacol. 54 [11], Seite 847-849.

[47] Bristow, M. R. (2000): beta-adrenergic receptor blockade in chronic heart failure, Circulation 101 [5], Seite 558-569.

[48] Otton, S. V.; Crewe, H. K.; Lennard, M. S.; Tucker, G. T. und Woods, H. F. (1988): Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes, J.Pharmacol.Exp.Ther. 247, Seite 242-247.

[49] Kim, M.; Shen, D. D.; Eddy, A. C.; Nelson, W. L. und Roskos, L. K. (1993): Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes, Drug Metab Dispos. 21, Seite 309-317.

[50] Lennard, M. S.; Tucker, G. T.; Silas, J. H.; Freestone, S.; Ramsay, L. E. und Woods, H. F. (1983): Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers, Clin.Pharmacol.Ther. 34, Seite 732-737.

[51] Cruickshank, J. M.; Neil-Dwyer, G.; Cameron, M. M. und McAinsh, J. (1980): beta-Adrenoreceptor-blocking agents and the blood-brain barrier, Clin.Sci.(Lond) 59 Suppl 6, Seite 453s-455s.

[52] Jordo, L.; Attman, P. O.; Aurell, M.; Johansson, L.; Johnsson, G. und Regardh, C. G. (1980): Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function, Clin.Pharmacokinet. 5, Seite 169-180.

[53] Hoffmann, K. J.; Regardh, C. G.; Aurell, M.; Ervik, M. und Jordo, L. (1980): The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites, Clin.Pharmacokinet. 5, Seite 181-191.

[54] Sherwood, A.; Allen, M. T.; Fahrenberg, J.; Kelsey, R. M.; Lovallo, W. R. und van Doornen, L. J. (1990): Methodological guidelines for impedance cardiography, Psychophysiology 27 [1], Seite 1-23.

[55] Bernstein, D. P. (1986): A new stroke volume equation for thoracic electrical bioimpedance: theory and rationale, Crit Care Med. 14 [10], Seite 904-909.

[56] Kollai, M. und Koizumi, K. (1981): Cardiovascular reflexes and interrelationships between sympathetic and parasympathetic activity, J.Auton.Nerv.Syst. 4 [2], Seite 135-148.

[57] Ewing, D. J.; Borsey, D. Q.; Bellavere, F. und Clarke, B. F. (1981): Cardiac autonomic neuropathy in diabetes: comparison of measures of R-R interval variation, Diabetologia 21 [1], Seite 18-24.

[58] Mosqueda-Garcia, R. (1995): Evaluation of Autonomic Failure In: Disorders of the Autonomic Nervous System. Robertson D, Biaggioni I, editors I[3], 25-54. 1995. Nashville, Harwood Academic Publishers. The Autonomic Nervous System. Burnstock, G.

[59] Palkovits, M. und Zaborszky, L. (1977): Neuroanatomy of central cardiovascular control. Nucleus tractus solitarii: afferent and efferent neuronal connections in relation to the baroreceptor reflex arc, Prog.Brain Res. 47, Seite 9-34.

[60] Levin, A. B. (1966): A simple test of cardiac function based upon the heart rate changes induced by the Valsalva maneuver, Am.J.Cardiol. 18 [1], Seite 90-99.

[61] Lind, AR; Taylor, SH; Humphreys, PW; Kennelly, BM und Donald, KW (1964): The circulatiory effects of sustained voluntary muscle contraction., Clin.Sci. 27, Seite 229-244.

[62] Freyschuss, U. (1970): Cardiovascular adjustment to somatomotor activation. The elicitation of increments in heart rate, aortic pressure and venomotor tone with the initiation of muscle contraction, Acta Physiol Scand.Suppl 342, Seite 1-63.

[63] Vissing, J.; MacLean, D. A.; Vissing, S. F.; Sander, M.; Saltin, B. und Haller, R. G. (2001): The exercise metaboreflex is maintained in the absence of muscle acidosis: insights from muscle microdialysis in humans with McArdle's disease, J.Physiol 537 [Pt 2], Seite 641-649.

[64] Goldstein, D. S.; Polinsky, R. J.; Garty, M.; Robertson, D.; Brown, R. T.; Biaggioni, I.; Stull, R. und Kopin, I. J. (1989): Patterns of plasma levels of catechols in neurogenic orthostatic hypotension, Ann.Neurol. 26 [4], Seite 558-563.

[65] (1996): Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, Circulation 93 [5], Seite 1043-1065.

[66] Omboni, S.; Parati, G.; Di Rienzo, M.; Wieling, W. und Mancia, G. (1996): Blood pressure and heart rate variability in autonomic disorders: a critical review, Clin.Auton.Res. 6 [3], Seite 171-182.

[67] Akselrod, S.; Gordon, D.; Ubel, F. A.; Shannon, D. C.; Berger, A. C. und Cohen, R. J. (1981): Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control, Science 213 [4504], Seite 220-222.

[68] Mayer, S. (1876): Über spontane Blutdruckschwankungen, Sber.Akad.Wiss.Wien 74, Seite 281.

[69] Bertinieri, G.; Di Rienzo, M.; Cavallazzi, A.; Ferrari, A. U.; Pedotti, A. und Mancia, G. (1985): A new approach to analysis of the arterial baroreflex, J.Hypertens.Suppl 3 Suppl 3, Seite S79-S81.

[70] Tank, J.; Jordan, J.; Diedrich, A.; Stoffels, M.; Franke, G.; Faulhaber, H. D.; Luft, F. C. und Busjahn, A. (2001): Genetic influences on baroreflex function in normal twins, Hypertension 37 [3], Seite 907-910.

[71] Pagani, M.; Lombardi, F.; Guzzetti, S.; Rimoldi, O.; Furlan, R.; Pizzinelli, P.; Sandrone, G.; Malfatto, G.; Dell'Orto, S.; Piccaluga, E. und . (1986): Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog, Circ.Res. 59 [2], Seite 178-193.

[72] Ferrannini, E. (1988): The theoretical bases of indirect calorimetry: a review, Metabolism 37 [3], Seite 287-301.

[73] Guyton, AC and Hall, J. E. (2000): Protein Metabolism In: Textbook of medical physiology. Guyton A, Hall JE, editors [10], 791-796.2000. Pilapelphia, W.B. Saunders.

[74] Shannon, J. R.; Flattem, N. L.; Jordan, J.; Jacob, G.; Black, B. K.; Biaggioni, I.; Blakely, R. D. und Robertson, D. (2000): Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency, N.Engl.J.Med. 342 [8], Seite 541-549.

[75] McMahon, F. G.; Fujioka, K.; Singh, B. N.; Mendel, C. M.; Rowe, E.; Rolston, K.; Johnson, F. und Mooradian, A. D. (2000): Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial, Arch.Intern.Med. 160 [14], Seite 2185-2191.

[76] Heal, D. J.; Prow, M. R. und Buckett, W. R. (1991): Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic alpha 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride, Psychopharmacology (Berl) 103 [2], Seite 251-257.

[77] Birkenfeld, AL; Schroeder, C; Tank, J; Luft, F. C. und Jordan, J. (2003): Cardiovascular effects of combined norepinephrine and serotonin transporter inhibition vs sole norepinephrine transporter inhibition. Abstract , Clincal Autonomic Research 13 [2], Seite 133-133.

[78] Kahan, T.; Hjemdahl, P. und Dahlof, C. (1984): Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle, Acta Physiol Scand. 122 [4], Seite 571-582.

[79] Goldstein, D. S.; Brush, J.-E. Jr; Eisenhofer, G.; Stull, R. und Esler, M. (1988): In vivo measurement of neuronal uptake of norepinephrine in the human heart, Circulation 78 [1], Seite 41-48.

[80] McLeod, J. G. und Tuck, R. R. (1987): Disorders of the autonomic nervous system: Part 2. Investigation and treatment, Ann.Neurol. 21 [6], Seite 519-529.

[81] Woolard, Jeanette; Bennett, Terence; Dunn, William R.; Heal, David J.; Aspley, Susan und Gardiner, Sheila M. (2004): Acute Cardiovascular Effects of Sibutramine in Conscious Rats, Journal of Pharmacology And Experimental Therapeutics 308 [3], Seite 1102-1110. URL: http://jpet.aspetjournals.org/cgi/content/abstract/308/3/1102

[82] Preiss, G. und Polosa, C. (1974): Patterns of sympathetic neuron activity associated with Mayer waves, Am.J.Physiol 226 [3], Seite 724-730.

[83] Landsberg, L. und Krieger, D. R. (1989): Obesity, metabolism, and the sympathetic nervous system, Am.J.Hypertens. 2, Seite 125S-132S.

[84] Masuo, K.; Mikami, H.; Ogihara, T. und Tuck, M. L. (2001): Familial obesity, sympathetic activation and blood pressure level, Blood Press 10 [4], Seite 199-204.

[85] Hansen, D. L.; Toubro, S.; Stock, M. J.; Macdonald, I. A. und Astrup, A. (1999): The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction, Int.J.Obes.Relat Metab Disord. 23 [10], Seite 1016-1024.

[86] van Baak, M. A.; van Mil, E.; Astrup, A. V.; Finer, N.; Van Gaal, L. F.; Hilsted, J.; Kopelman, P. G.; Rossner, S.; James, W. P. und Saris, W. H. (2003): Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial), Am.J.Clin.Nutr. 78 [2], Seite 209-214.

[87] Sramek, J. J.; Leibowitz, M. T.; Weinstein, S. P.; Rowe, E. D.; Mendel, C. M.; Levy, B.; McMahon, F. G.; Mullican, W. S.; Toth, P. D. und Cutler, N. R. (2002): Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial, J.Hum.Hypertens. 16 [1], Seite 13-19.

[88] Esler, M.; Jackman, G.; Leonard, P.; Skews, H.; Bobik, A. und Jennings, G. (1981): Effect of propranolol on noradrenaline kinetics in patients with essential hypertension, Br.J.Clin.Pharmacol. 12, Seite 375-380.

[89] Tank, J.; Diedrich, A.; Schroeder, C.; Stoffels, M.; Franke, G.; Sharma, A. M.; Luft, F. C. und Jordan, J. (2001): Limited effect of systemic beta-blockade on sympathetic outflow, Hypertension 38 [6], Seite 1377-1381.

[90] Jordan, J. und Sharma, A. M. (2003): Potential for sibutramine-yohimbine interaction?, Lancet 361 [9371], Seite 1826.

[91] Sharma, A. M.; Pischon, T.; Hardt, S.; Kunz, I. und Luft, F. C. (2001): Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis, Hypertension 37 [2], Seite 250-254.

[92] Esler, M.; Hastings, J.; Lambert, G.; Kaye, D.; Jennings, G. und Seals, D. R. (2002): The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover, Am.J.Physiol Regul.Integr.Comp Physiol 282 [3], Seite R909-R916.

[93] Hinojosa-Laborde, C.; Chapa, I.; Lange, D. und Haywood, J. R. (1999): Gender differences in sympathetic nervous system regulation, Clin.Exp.Pharmacol.Physiol 26 [2], Seite 122-126.

[94] Manolio, T. A.; Fishel, S. C.; Beattie, C.; Torres, J.; Christopherson, R.; Merritt, W. T. und Whelton, P. K. (1988): Evaluation of the Dinamap continuous blood pressure monitor, Am.J.Hypertens. 1, Seite 161S-167S.

[95] Petersen, M. E.; Williams, T. R. und Sutton, R. (1995): A comparison of non-invasive continuous finger blood pressure measurement (Finapres) with intra-arterial pressure during prolonged head-up tilt, Eur.Heart J. 16, Seite 1641-1654.

[96] Jagomagi, K.; Raamat, R. und Talts, J. (2001): Effect of altering vasoactivity on the measurement of finger blood pressure, Blood Press Monit. 6 [1], Seite 33-40.

[97] Jellema, W. T.; Imholz, B. P.; van Goudoever, J.; Wesseling, K. H. und van Lieshout, J. J. (1996): Finger arterial versus intrabrachial pressure and continuous cardiac output during head-up tilt testing in healthy subjects, Clin.Sci.(Lond) 91, Seite 193-200.

[98] Esler, M.; Jennings, G.; Korner, P.; Willett, I.; Dudley, F.; Hasking, G.; Anderson, W. und Lambert, G. (1988): Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover, Hypertension 11 [1], Seite 3-20.

[99] Ninomiya, I.; Irisawa, A. und Nisimaru, N. (1973): Nonuniformity of sympathetic nerve activity to the skin and kidney, Am.J.Physiol 224 [2], Seite 256-264.

[100] Leimbach, W.-N. Jr; Wallin, B. G.; Victor, R. G.; Aylward, P. E.; Sundlof, G. und Mark, A. L. (1986): Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure, Circulation 73 [5], Seite 913-919.

[101] Anderson, E. A.; Sinkey, C. A.; Lawton, W. J. und Mark, A. L. (1989): Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings, Hypertension 14 [2], Seite 177-183.

[102] Carruthers, M.; Conway, N.; Somerville, W.; Taggart, P. und Bates, D. (1970): Validity of plasma-catecholamine estimations, Lancet 1 [7663], Seite 62-67.

[103] Dimsdale, J. E. und Ziegler, M. G. (1991): What do plasma and urinary measures of catecholamines tell us about human response to stressors?, Circulation 83 [4 Suppl], Seite II36-II42.

[104] Pickett, B. R. und Buell, J. C. (1992): Validity of cardiac output measurement by computer-averaged impedance cardiography, and comparison with simultaneous thermodilution determinations, Am.J.Cardiol. 69 [16], Seite 1354-1358.

[105] Pickett, B. R. und Buell, J. C. (1992): Validity of cardiac output measurement by computer-averaged impedance cardiography, and comparison with simultaneous thermodilution determinations, Am.J.Cardiol. 69, Seite 1354-1358.

[106] Ebert, T. J.; Eckberg, D. L.; Vetrovec, G. M. und Cowley, M. J. (1984): Impedance cardiograms reliably estimate beat-by-beat changes of left ventricular stroke volume in humans, Cardiovasc.Res. 18, Seite 354-360.

[107] Di Girolamo, E.; Di Iorio, C.; Leonzio, L.; Sabatini, P. und Barsotti, A. (1999): Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study, Circulation 100 [17], Seite 1798-1801.

[108] Ainslie, P.; Reilly, T. und Westerterp, K. (2003): Estimating human energy expenditure: a review of techniques with particular reference to doubly labelled water, Sports Med.2003.;33.(9.):683.-98. 33, Seite 683-698.

[109] Hayano, J.; Sakakibara, Y.; Yamada, A.; Yamada, M.; Mukai, S.; Fujinami, T.; Yokoyama, K.; Watanabe, Y. und Takata, K. (1991): Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects, Am.J.Cardiol. 67, Seite 199-204.

[110] Cohen, M. A. und Taylor, J. A. (2002): Short-term cardiovascular oscillations in man: measuring and modelling the physiologies, J.Physiol 542 [Pt 3], Seite 669-683.

[111] Eckberg, D. L. (1998): Sympathovagal balance: a critical appraisal. Reply, Circulation 98, Seite 2643-2644.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
11.11.2004